Please note: We are currently experiencing some performance issues across the site, and some pages may be slow to load. We are working on restoring normal service soon. Importing new articles from Word documents is also currently unavailable. We apologize for any inconvenience.

loading page

Temporal Findings of Erdheim-Chester Disease A Case Report and Review of the Literature
  • +1
  • Jie Tang,
  • * Wang,Tao,
  • * Tang,FengZhu,
  • ShenHong Qu
Jie Tang
People's Hospital of Guangxi Zhuang Autonomous Region
Author Profile
* Wang,Tao
People's Hospital of Guangxi Zhuang Autonomous Region
Author Profile
* Tang,FengZhu
People's Hospital of Guangxi Zhuang Autonomous Region
Author Profile
ShenHong Qu
People's Hospital of Guangxi Zhuang Autonomous Region

Corresponding Author:[email protected]

Author Profile

Abstract

Introduction: Erdheim-Chester Disease (ECD) is a rare non-Langerhans cell histiocytic disorder, first described in 1930. Its diverse manifestations range from asymptomatic bone lesions to severe systemic involvement. Herein, we report a novel case of ECD presenting with temporal bone pain, a symptom not previously described in the literature. Methods: We observed and analyzed the symptoms, clinical history, and imaging manifestations of a patient presenting with significant temporal bone pain. The diagnosis was confirmed via a biopsy. We also investigated the presence of the BRAFV600E mutation, which is known to be present in over half of ECD cases. Results: The patient presented with significant temporal bone pain on pressure but exhibited no clinical signs of urinary collapse or neurological symptoms. Imaging studies showed typical signs of ECD, and a biopsy confirmed the diagnosis. Genetic testing revealed the presence of the BRAFV600E mutation. Conclusion: This case extends our understanding of the clinical manifestations of ECD and highlights the potential for variable symptomatology. Temporal bone pain may be a novel presentation of ECD, emphasizing the need for a high index of suspicion and thorough evaluation in patients presenting with unexplained bone pain. The confirmation of the BRAFV600E mutation in this patient underlines its potential as a therapeutic target in ECD. Future research is necessary to fully elucidate the clinical significance and treatment implications of this novel presentation.